news

Jan 24, 2022 – MyBiotics announces successful completion of the Phase 1 trial for its MBX–SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies [...]

06 Apr, 2021 – MyBiotics Pharma Ltd. and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center, announced today that they have [...]

Feb 17, 2021 – Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based [...]

03 Feb, 2021 – MyBiotics Pharma announced today that it has received an investment from Mii Fund, a partnership with Maruho Co. Ltd., Japan’s preeminent leader in dermatology. [...]

09 Nov, 2020 – Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and MyBiotics Pharma Ltd. announced they have entered into a research and development collaboration agreement to identify and [...]

Oct 21, 2020 – MyBiotics was awarded 2.0 million Euros ($2.3 million) by the European Union as part of its Horizon 2020 Program. The grant will support the development of a novel technology [...]

Mybiotics was selected as a winner of the contest to participate in the Israel Pavilion at Bio 2016 conference in San Francisco.